2014 News Releases

2014 | 2013 | 2012
 
DateTitle 
07/10/14Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced MelanomaPrinter Friendly Version
07/07/14Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual RegimenPrinter Friendly Version
07/01/14Bristol-Myers Squibb to Announce Results for Second Quarter on July 24Printer Friendly Version
06/27/14Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PEPrinter Friendly Version
06/27/14Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European UnionPrinter Friendly Version
06/24/14Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped EarlyPrinter Friendly Version
06/24/14Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research InstitutePrinter Friendly Version
06/17/14Bristol-Myers Squibb Announces DividendPrinter Friendly Version
06/12/14U.S. Court of Appeals Denies Appeal in Baraclude Patent CasePrinter Friendly Version
06/10/14AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia® (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with Early Rheumatoid Arthritis (RA)Printer Friendly Version
06/09/14Giovanni Caforio, M.D., Appointed Chief Operating Officer and Elected to Board of DirectorsPrinter Friendly Version
06/03/14Bristol-Myers Squibb to Take Part in Goldman Sachs 35th Annual Global Health Care ConferencePrinter Friendly Version
06/03/14Bristol-Myers Squibb and Syngene International Extend Research CollaborationPrinter Friendly Version
06/02/14Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free SurvivalPrinter Friendly Version
06/02/14One- & Two-Year Survival Rates of 94% and 88% Announced from Phase 1b Trial of Investigational PD-1 Checkpoint Inhibitor Nivolumab and Yervoy® (ipilimumab) in Advanced Melanoma; Ongoing Phase 2/3 Trials to Confirm ResultsPrinter Friendly Version
05/27/14Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology TargetsPrinter Friendly Version
05/27/14Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel ImmunotherapiesPrinter Friendly Version
05/21/14Bristol-Myers Squibb to Present New Remission Data on ORENCIA® (abatacept) and Clazakizumab at The European League Against Rheumatism (EULAR) 2014 Annual MeetingPrinter Friendly Version
05/19/14Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple MyelomaPrinter Friendly Version
05/16/14Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO HighlightsPrinter Friendly Version
05/14/14In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy® (ipilimumab)Printer Friendly Version
05/14/14Bristol-Myers Squibb Announces Two- and Three-Year Survival Data for Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Advanced Melanoma Cohort of a Phase 1b StudyPrinter Friendly Version
05/14/14Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase 1b Non-Small Cell Lung Cancer TrialsPrinter Friendly Version
05/14/14Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough Therapy Designation for Hodgkin LymphomaPrinter Friendly Version
05/14/14Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and VarlilumabPrinter Friendly Version
05/12/14Bristol-Myers Squibb to Present at UBS Global Healthcare ConferencePrinter Friendly Version
05/06/14Bristol-Myers Squibb Announces Retirement of Brian DanielsPrinter Friendly Version
05/05/14Bristol-Myers Squibb Continues to Lead the Advancement of Immuno-Oncology with Broad Set of New Data at 2014 American Society of Clinical Oncology (ASCO) Annual MeetingPrinter Friendly Version
04/29/14Bristol-Myers Squibb Reports First Quarter 2014 Financial ResultsPrinter Friendly Version
04/29/14Bristol-Myers Squibb Acquires iPierian, Inc.Printer Friendly Version
04/24/14Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens ListPrinter Friendly Version
04/22/14Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing AgreementPrinter Friendly Version
04/14/14Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1Printer Friendly Version
04/10/14Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C PatientsPrinter Friendly Version
04/07/14Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis CPrinter Friendly Version
04/01/14Bristol-Myers Squibb to Announce Results for First Quarter 2014 on April 29Printer Friendly Version
03/24/14Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple Investigational All-oral Combinations across Hepatitis C Genotypes at The International Liver CongressTMPrinter Friendly Version
03/17/14Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint PathwaysPrinter Friendly Version
03/05/14Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced PatientsPrinter Friendly Version
03/03/14Bristol-Myers Squibb Announces DividendPrinter Friendly Version
03/03/14Bristol-Myers Squibb Announces Charitable Donation of $1 Million to Support Immuno-Oncology Education for Patients and CaregiversPrinter Friendly Version
02/24/14Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis CPrinter Friendly Version
02/21/14In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial FibrillationPrinter Friendly Version
02/20/14Bristol-Myers Squibb to Present at Cowen and Company 34th Annual Global Health Care ConferencePrinter Friendly Version
02/14/14Bristol-Myers Squibb to Present at Citi 2014 Global Health Care ConferencePrinter Friendly Version
02/05/14Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care ConferencePrinter Friendly Version
02/03/14Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZenecaPrinter Friendly Version
01/24/14Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial ResultsPrinter Friendly Version
01/16/14AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research InitiativePrinter Friendly Version
01/13/14U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 DiabetesPrinter Friendly Version
01/08/14AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga™ (dapagliflozin)Printer Friendly Version
01/08/14Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines AgencyPrinter Friendly Version
01/06/14Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24Printer Friendly Version
01/06/14Bristol-Myers Squibb to Present at J.P. Morgan Healthcare ConferencePrinter Friendly Version
01/03/14Bristol-Myers Squibb to Take Part in Goldman Sachs Healthcare CEOs Unscripted ConferencePrinter Friendly Version

Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available from the Securities and Exchange Commission, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the company’s website at www.bms.com.